$IPSI
Innovative Payment Solutions, Inc. Stock $ipsi

$ipsi Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023039367 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$5.00	$433.00	$0.00
YoY Change
Cost Of Revenue	$284.00	$2.085K
YoY Change
Gross Profit	-$279.00	-$1.652K
YoY Change
Gross Profit Margin	-5580.0%	-381.52%
Selling, General & Admin	$1.058M	$965.2K	$869.4K
YoY Change	32.94%	11.02%	-82.59%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$139.0K	$140.7K	$4.500K
YoY Change	2991.28%	3026.44%	7.91%
% of Gross Profit
Operating Expenses	$1.197M	$1.106M	$873.9K
YoY Change	49.57%	26.55%	-82.5%
Operating Profit	-$1.197M	-$1.108M	-$873.9K
YoY Change	49.61%	26.74%	-82.5%
Interest Expense	$69.32K	$832.6K	-$216.8K
YoY Change	-124.13%	-484.0%	-82.17%
% of Operating Profit
Other Income/Expense, Net	$0.00	$59.74K	-$719.6K
YoY Change		-108.3%	-1539.12%
Pretax Income	-$2.652M	-$275.0K	-$1.810M
YoY Change	143.89%	-84.81%	-84.11%
Income Tax
% Of Pretax Income
Net Earnings	-$3.174M	-$273.4K	-$1.810M
YoY Change	195.45%	-84.9%	-84.11%
Net Earnings / Revenue	-63484340.0%	-63138.57%
Basic Earnings Per Share	-$0.01	$0.00	$0.00
Diluted Earnings Per Share	-$0.01	$0.00	-$4.897K
COMMON SHARES
Basic Shares Outstanding	376.9M shares	376.9M shares	367.9M shares
Diluted Shares Outstanding	377.9M shares	376.9M shares	376.9M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$46.79K	$155.9K	$3.363M
YoY Change	-98.15%	-95.36%	-55.72%
Cash & Equivalents	$373.8K	$155.9K
Short-Term Investments
Other Short-Term Assets	$19.08K	$75.09K	$39.33K
YoY Change	-28.6%	90.91%	376.15%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$254.6K	$231.0K	$3.402M
YoY Change	-90.05%	-93.21%	-55.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.86K	$25.53K	$24.30K
YoY Change	-24.97%	5.05%	-67.44%
Goodwill
YoY Change
Intangibles	$1.192M	$1.632M
YoY Change	23.53%
Long-Term Investments	$306.8K	$500.0K	$500.0K
YoY Change	-38.63%	0.0%
Other Assets	$84.57K	$47.59K	$34.80K
YoY Change	143.02%	36.75%	295.45%
Total Long-Term Assets	$1.598M	$2.205M	$1.426M
YoY Change	5.18%	54.58%	1609.49%
TOTAL ASSETS
Total Short-Term Assets	$254.6K	$231.0K	$3.402M
Total Long-Term Assets	$1.598M	$2.205M	$1.426M
Total Assets	$1.853M	$2.436M	$4.828M
YoY Change	-54.57%	-49.55%	-37.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.387M	$889.0K	$522.3K
YoY Change	242.7%	70.23%	211.46%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$3.900M	$3.621M	$1.753M
YoY Change	117.03%	106.53%	527.66%
Long-Term Debt Due	$3.280K	$3.220K
YoY Change
Total Short-Term Liabilities	$8.303M	$6.123M	$2.590M
YoY Change	200.96%	136.37%	-49.39%
LONG-TERM LIABILITIES
Long-Term Debt	$158.4K	$160.0K	$159.7K
YoY Change	-1.73%	0.13%	3.65%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$158.4K	$160.0K	$159.7K
YoY Change	-1.73%	0.13%	3.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.303M	$6.123M	$2.590M
Total Long-Term Liabilities	$158.4K	$160.0K	$159.7K
Total Liabilities	$8.462M	$6.283M	$2.777M
YoY Change	189.77%	126.28%	-47.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$55.85M	-$52.67M
YoY Change	24.14%
Common Stock	$37.91K	$37.69K
YoY Change	3.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.609M	-$3.847M	$2.052M
YoY Change
Total Liabilities & Shareholders Equity	$1.853M	$2.436M	$4.828M
YoY Change	-54.57%	-49.55%	-37.18%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$3.174M	-$273.4K	-$1.810M
YoY Change	195.45%	-84.9%	-84.11%
Depreciation, Depletion And Amortization	$139.0K	$140.7K	$4.500K
YoY Change	2991.28%	3026.44%	7.91%
Cash From Operating Activities	-$244.9K	-$688.3K	-$760.9K
YoY Change	-64.6%	-9.54%	-1.71%
INVESTING ACTIVITIES
Capital Expenditures		$64.78K	-$179.0K
YoY Change		-136.18%
Acquisitions
YoY Change
Other Investing Activities	-$215.9K	-$64.78K	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$215.9K	-$64.78K	-$179.0K
YoY Change	45.1%	-63.81%	3629.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	351.6K	$534.2K	-1.147M
YoY Change	3543.83%	-146.57%	-113.86%
NET CHANGE
Cash From Operating Activities	-244.9K	-$688.3K	-760.9K
Cash From Investing Activities	-215.9K	-$64.78K	-179.0K
Cash From Financing Activities	351.6K	$534.2K	-1.147M
Net Change In Cash	-109.1K	-$218.9K	-2.087M
YoY Change	-86.87%	-89.51%	-127.83%
FREE CASH FLOW
Cash From Operating Activities	-$244.9K	-$688.3K	-$760.9K
Capital Expenditures		$64.78K	-$179.0K
Free Cash Flow		-$753.1K	-$581.9K
YoY Change		29.42%	-24.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-55648
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	33-1230229
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	56B 5th Avenue
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Lot 1 #AT
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Carmel By The Sea
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	93921
CY2023Q1	dei	City Area Code CityAreaCode	(866)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	477-4729
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	376901679	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	155868	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	374765	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	75085	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	97042	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	230953	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	471807	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25528	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40362	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1631739	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1692811	usd
CY2023Q1	us-gaap	Security Deposit SecurityDeposit	47592	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	47592	usd
CY2023Q1	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	500000	usd
CY2022Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	500000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	2204859	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	2280765	usd
CY2023Q1	us-gaap	Assets Assets	2435812	usd
CY2022Q4	us-gaap	Assets Assets	2752572	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	889042	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	761732	usd
CY2023Q1	us-gaap	Federal Home Loan Bank Advances Current FederalHomeLoanBankAdvancesCurrent	3217	usd
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent	988368	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	964268	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	228888	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
CY2023Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2632451	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2266602	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1609892	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2550642	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6122970	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6543244	usd
CY2023Q1	qpag	Federal Relief Loans Non Current FederalReliefLoansNonCurrent	159952	usd
CY2022Q4	qpag	Federal Relief Loans Non Current FederalReliefLoansNonCurrent	163978	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	159952	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	163978	usd
CY2023Q1	us-gaap	Liabilities Liabilities	6282922	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6707222	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	376901679	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	376901679	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	376901679	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	376901679	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	37690	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	37690	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	48788448	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	48405921	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52673248	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	94466	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	62766	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-52399858	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-3847110	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3956247	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	1597	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3847110	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3954650	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2435812	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2752572	usd
CY2023Q1	us-gaap	Revenues Revenues	433	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2085	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	-1652	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	965207	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	869387	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	140690	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4496	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1105897	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	873883	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1107549	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-873883	usd
CY2022Q1	qpag	Penalty On Convertible Debt PenaltyOnConvertibleDebt	-719558	usd
CY2023Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	85221	usd
CY2022Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	45766	usd
CY2023Q1	qpag	Amortization Of Debt Discount AmortizationOfDebtDiscount	-22967	usd
CY2022Q1	qpag	Amortization Of Debt Discount AmortizationOfDebtDiscount	-263200	usd
CY2023Q1	qpag	Derivative Liability Movement DerivativeLiabilityMovement	-940750	usd
CY2022Q1	qpag	Derivative Liability Movement DerivativeLiabilityMovement	-92161	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-274987	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1810246	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-274987	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-1810246	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1597	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-8752	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-273390	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1801494	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	376901679	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	367901679	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3954650	usd
CY2023Q1	qpag	Stock Issued During Period Value Fair Value Of Warrants Issued StockIssuedDuringPeriodValueFairValueOfWarrantsIssued	251856	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	130671	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-274987	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-3847110	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3731312	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-1810246	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2078298	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-274987	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-1810246	usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-940750	usd
CY2022Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-92161	usd
CY2023Q1	us-gaap	Depreciation Depreciation	140690	usd
CY2022Q1	us-gaap	Depreciation Depreciation	4496	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	22967	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	263200	usd
CY2022Q1	qpag	Penalty On Convertible Debt PenaltyOnConvertibleDebt	-719558	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	130671	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	157232	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-21957	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-45708	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	127311	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6221	usd
CY2023Q1	qpag	Increase Decrease In Interest Accruals IncreaseDecreaseInInterestAccruals	83837	usd
CY2022Q1	qpag	Increase Decrease In Interest Accruals IncreaseDecreaseInInterestAccruals	-42484	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-688304	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-760918	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	64783	usd
CY2022Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	179030	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-64783	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-179030	usd
CY2023Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	535000	usd
CY2022Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1147063	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	809	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	534191	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1147063	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-218896	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2087011	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	374765	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5449751	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	155869	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	3362740	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	1384	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	88250	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	251856	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	621920	shares
CY2023Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	2500	shares
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	500000	usd
CY2019Q4	us-gaap	Excess Stock Shares Outstanding ExcessStockSharesOutstanding	32047817	shares
CY2019Q4	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	2250000	shares
CY2019Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	2250000	shares
CY2019Q4	qpag	Percentage Of Shares Vivi PercentageOfSharesVivi	0.09	pure
CY2021Q3	qpag	Percentage Of Remaining Shares Owned PercentageOfRemainingSharesOwned	0.49	pure
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>c)</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Use of Estimates</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions, which are evaluated on an ongoing basis, that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the amounts of revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and judgments. In particular, significant estimates and judgments include those related to, the estimated useful lives for plant and equipment, the fair value of long-lived investments, the fair value of warrants and stock options granted for services or compensation, estimates of the probability and potential magnitude of contingent liabilities, derivative liabilities, the valuation allowance for deferred tax assets due to continuing operating losses and the allowance for doubtful accounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from our estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q1	us-gaap	Investments Investments	500000	usd
CY2022Q4	us-gaap	Investments Investments	500000	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt"><b>f)</b></span></td><td style="text-align: justify"><span style="font-size: 10pt"><b>Risks and Uncertainties</b></span></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company’s operations are and will be subject to significant risks and uncertainties including financial, operational, regulatory, and other risks, including the potential risk of business failure. These risks include, without limitation, risks associated with (i) COVID-19 and its variants, (ii) launching and scaling the Company’s e-wallet and related products and the use by customers of such products, (iii) developing and implementing successful marketing campaigns and other strategic initiatives; (iv) competition, (iv) compliance with applicable laws, rules and regulations (including those related to fund remittance); (v) the Company’s outstanding indebtedness, including the Company’s ability to repay or extend the maturity of such indebtedness (see Note 8); (vi) inflation and other economic factors and (vii) the Company’s ability to obtain necessary financing. These conditions may not only limit the Company’s access to capital, but also make it difficult for its customers, vendors and the Company to accurately forecast and plan future business activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company’s results may also be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, and rates and methods of taxation, among other things. Many of these risks are beyond the Company’s control and are unpredictable. The Company may be unable to adequately manage such risks and similar risks, which could impair the viability of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2023Q1	qpag	Federally Insured Limit FederallyInsuredLimit	0	usd
CY2022Q4	qpag	Federally Insured Limit FederallyInsuredLimit	120580	usd
CY2023Q1	qpag	Equity Methods Investment Ownership Percentage EquityMethodsInvestmentOwnershipPercentage	0.20	pure
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1000	usd
CY2023Q1	qpag	Schedule Of Estimated Useful Lives Of Assets ScheduleOfEstimatedUsefulLivesOfAssets	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 49%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Description</b></span></td> <td style="width: 2%"> </td> <td style="width: 49%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>Estimated Useful Life</b></span></td></tr> <tr> <td> </td> <td> </td> <td> </td></tr> <tr style="background-color: #CCEEFF"> <td><span style="font-size: 10pt">Kiosks (not used in the Company’s current business)</span></td> <td> </td> <td><span style="font-size: 10pt">7 years</span></td></tr> <tr> <td> </td> <td> </td> <td> </td></tr> <tr style="background-color: #CCEEFF"> <td><span style="font-size: 10pt">Computer equipment</span></td> <td> </td> <td><span style="font-size: 10pt">3 years</span></td></tr> <tr> <td> </td> <td> </td> <td> </td></tr> <tr style="background-color: #CCEEFF"> <td><span style="font-size: 10pt">Office equipment</span></td> <td> </td> <td><span style="font-size: 10pt">10 years</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p>
CY2023Q1	us-gaap	Revenues Net Of Interest Expense RevenuesNetOfInterestExpense	433	usd
CY2022Q1	us-gaap	Revenues Net Of Interest Expense RevenuesNetOfInterestExpense	0	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	274987	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	10331424	usd
CY2021Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	250000	usd
CY2021Q3	qpag	Fintech Percentage FintechPercentage	0.51	pure
CY2021Q3	qpag	Owned Frictionless Financial Technologies OwnedFrictionlessFinancialTechnologies	0.49	pure
CY2022	qpag	Additional Amount Of Software AdditionalAmountOfSoftware	41320	usd
CY2023Q1	qpag	Additional Amount Of Software AdditionalAmountOfSoftware	35891	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	375000	usd
CY2022	us-gaap	Payments For Software PaymentsForSoftware	1127400	usd
CY2023Q1	us-gaap	Payments For Software PaymentsForSoftware	28893	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Cost Incurred To Renew Or Extend FiniteLivedIntangibleAssetsCostIncurredToRenewOrExtend	1858504	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-226765	usd
CY2023Q1	us-gaap	Sale Leaseback Transaction Net Book Value SaleLeasebackTransactionNetBookValue	1631739	usd
CY2022Q4	us-gaap	Sale Leaseback Transaction Net Book Value SaleLeasebackTransactionNetBookValue	1692811	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	125856	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2023Q1	qpag	Additional Irrecvocable Right To Acquire Outstanding Common Stock Percentage AdditionalIrrecvocableRightToAcquireOutstandingCommonStockPercentage	0.01	pure
CY2023Q1	us-gaap	Lessor Operating Lease Description LessorOperatingLeaseDescription	The lease commenced on April 1, 2021 and is for a twelve month period, terminating on April 1, 2022.
CY2023Q1	us-gaap	Lease Cost LeaseCost	4800	usd
CY2023Q1	qpag	Monthly Rent MonthlyRent	5088	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	15264	usd
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	14400	usd
CY2023Q1	qpag	Schedule Of Other Lease Information ScheduleOfOtherLeaseInformation	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months<br/> ended<br/> March 31,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months<br/> ended<br/> March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Cash paid for amounts included in the measurement of lease liabilities</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating cash flows from operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(15,264</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(14,400</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Remaining lease term – operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">Monthly</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-size: 10pt">Monthly</span></td><td style="text-align: left"> </td></tr> </table>
CY2023Q1	qpag	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-15264	usd
CY2022Q1	qpag	Operating Cash Flows From Operating Leases OperatingCashFlowsFromOperatingLeases	-14400	usd
CY2023Q1	qpag	Remaining Lease Term Operating Lease RemainingLeaseTermOperatingLease	Monthly
CY2022Q1	qpag	Remaining Lease Term Operating Lease RemainingLeaseTermOperatingLease	Monthly
CY2020Q3	qpag	Disaster Loan Amount DisasterLoanAmount	150000	usd
CY2020Q3	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.0375	pure
CY2020Q3	qpag	Repayable Installments RepayableInstallments	731	usd
CY2023Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	809	usd
CY2023Q1	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	1384	usd
CY2023Q1	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	149191	usd
CY2023Q1	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	13978	usd
CY2023Q1	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	3217	usd
CY2021Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	500500	usd
CY2021Q1	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.125	pure
CY2021Q1	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	2486957	shares
CY2021Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.24
CY2021Q1	us-gaap	Notes Issued1 NotesIssued1	964000	usd
CY2021Q1	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	43608	usd
CY2021Q1	us-gaap	Convertible Debt ConvertibleDebt	920392	usd
CY2023Q1	qpag	Debt Instruments Face Amount DebtInstrumentsFaceAmount	964000	usd
CY2023Q1	us-gaap	Line Of Credit Facility Increase Accrued Interest LineOfCreditFacilityIncreaseAccruedInterest	24368	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	988368	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	964268	usd
CY2023Q1	us-gaap	Other Noninterest Expense OtherNoninterestExpense	24100	usd
CY2022Q1	us-gaap	Other Noninterest Expense OtherNoninterestExpense	0	usd
CY2021Q1	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	500500	usd
CY2021Q1	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	572000	usd
CY2021Q1	us-gaap	Shares Issued SharesIssued	2486957	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.24
CY2022Q1	us-gaap	Debt Instrument Maturity Date Range End1 DebtInstrumentMaturityDateRangeEnd1	2022-08-16
CY2022Q1	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	3000000	shares
CY2023Q1	us-gaap	Shares Issued SharesIssued	3000000	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	39130435	shares
CY2021Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	482000	usd
CY2021Q1	us-gaap	Debt Instrument Maturity Date Range End1 DebtInstrumentMaturityDateRangeEnd1	2023-12-30
CY2021Q1	qpag	Debt Instruments Interest Rate Stated Percentage DebtInstrumentsInterestRateStatedPercentage	0.10	pure
CY2021Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	51901711	shares
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.06
CY2022Q4	qpag	Aggregate Amount AggregateAmount	2264784	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.0115
CY2023Q1	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	836414	usd
CY2023Q1	qpag	Black Scholes Valuation Model BlackScholesValuationModel	1499577	usd
CY2023Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	238182	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	920392	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	43608	usd
CY2023Q1	us-gaap	Senior Notes SeniorNotes	964000	usd
CY2023Q1	qpag	Holders Amounting HoldersAmounting	841003	usd
CY2022Q4	qpag	Fair Value Adjustment To Derivative Liability FairValueAdjustmentToDerivativeLiability	-411752	usd
CY2023Q1	us-gaap	Other Expenses OtherExpenses	59737	usd
CY2022	us-gaap	Other Expenses OtherExpenses	44379	usd
CY2023Q1	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	22967	usd
CY2022	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	263200	usd
CY2023Q1	qpag	Gross Proceeds GrossProceeds	535000	usd
CY2023Q1	qpag	Gross Proceeds GrossProceeds	535000	usd
CY2023Q1	qpag	Purchase Of Aggregate Shares PurchaseOfAggregateShares	46521739	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.0115
CY2023Q1	qpag	Debt Instruments Interest Rate Stated Percentage DebtInstrumentsInterestRateStatedPercentage	0.08	pure
CY2023Q1	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	0.0115
CY2023Q1	qpag	Beneficially Own Of Percentage BeneficiallyOwnOfPercentage	0.0499	pure
CY2023Q1	qpag	Limitation Exceeds Percentage LimitationExceedsPercentage	0.0999	pure
CY2023Q1	qpag	Debt Instrument Accrued Interest DebtInstrumentAccruedInterest	311261	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	228888	usd
CY2023Q1	qpag	Rachet Provision RachetProvision	474614	usd
CY2023Q1	us-gaap	Derivative Liability Notional Amount DerivativeLiabilityNotionalAmount	940750	usd
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price Increase DebtInstrumentConvertibleConversionPriceIncrease	0.0115
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Derivative Cash Received On Hedge DerivativeCashReceivedOnHedge	2550642	usd
CY2022Q4	us-gaap	Derivative Cash Received On Hedge DerivativeCashReceivedOnHedge	407161	usd
CY2022Q4	qpag	Derivative Financial Liability Arising From Convertible Note DerivativeFinancialLiabilityArisingFromConvertibleNote	238182	usd
CY2022Q4	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	2317051	usd
CY2023Q1	qpag	Fair Value Adjustment To Derivative Liability FairValueAdjustmentToDerivativeLiability	-940750	usd
CY2023Q1	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	1609892	usd
CY2022Q4	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	2550642	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	376901679	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	376901679	shares
CY2023Q1	qpag	Restricted Stock Granted Shares RestrictedStockGrantedShares	23495000	shares
CY2023Q1	qpag	Restricted Stock Granted Weighted Average Fair Value Per Share RestrictedStockGrantedWeightedAverageFairValuePerShare	0.05
CY2023Q1	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	62766	usd
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	(i) a cash endorsement fee of Three Hundred Thousand U.S. Dollars ($300,000 USD), payable as follows: (i) One Hundred Twenty-Five Thousand Dollars ($125,000) upon execution of the Endorsement Agreement, (ii) One Hundred Twenty-Five Thousand Dollars ($125,000) quarterly during the Term, beginning on the 90th day following the Effective Date, and (iii) Fifty Thousand Dollars ($50,000) on or prior to the first anniversary of the Effective Date and (ii) warrants exercisable for an aggregate of Fifteen Million (15,000,000) shares of the Common Stock at an exercise price of $0.0345 per share. The Warrants shall have a three-year term commencing from the Effective Date.
CY2022Q3	qpag	Expiration Dates ExpirationDates	2027-08-30
CY2022Q4	qpag	Note Amendment Transaction Description NoteAmendmentTransactionDescription	the Company entered into the December 2022 Note Amendment Transaction, as fully described in note 9 above. In terms of the Note Amendment Transaction the following occurred: ● The warrants issued to Cavalry and Mercer exercisable for 4,973,914 shares of common stock (2,486,957 for each of Cavalry and Mercer), were exchanged for two promissory notes of $482,000 each, as disclosed in note 8 above; ● The warrants issued to Cavalry and Mercer on August 30, 2022, were subject to repricing and a full rachet increase in the number of warrants issued, resulting in an increase in the number of warrants by 72,260,870 (36,130,435 to each Cavalry and Mercer) and a reset of the exercise price to $0.0115 per share. The additional warrants were valued at $841,003 using a Black-Scholes valuation model and was expensed in the statement of operations as a component of the loss on convertible debt. ● An additional 13,736,857 warrants previously issued to Mercer, Iroquois Master Fund and Bellridge Capital LP were subject to repricing of the exercise price from a range of $0.05 to $0.15 per share to $0.0115 per share. The change in the fair value of these warrants of $20,079, using a Black-Scholes valuation model was recorded as a component of the loss on convertible debt.
CY2023Q1	us-gaap	Sale Of Stock Percentage Of Ownership Before Transaction SaleOfStockPercentageOfOwnershipBeforeTransaction	0.0999	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.15
CY2023Q1	qpag	Options Exercisable Number Exercisablein OptionsExercisableNumberExercisablein	39233333	shares
CY2023Q1	qpag	Options Exercisable Weighted Average Exercise Price OptionsExercisableWeightedAverageExercisePrice	0.15
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	201112800	shares
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P4Y2M4D
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.0256
CY2023Q1	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	196425300	shares
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.0256
CY2023Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P4Y2M23D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q3	qpag	Options Exercisable Shares OptionsExercisableShares	200000	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.04
CY2022	qpag	Amount Of Immediate Expense AmountOfImmediateExpense	31970	usd
CY2023Q1	qpag	Share Based Compensation Arrangements By Share Based Payment Award Option Outstanding ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionOutstanding	46316666	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y8M8D
CY2023Q1	qpag	Penalty On Convertible Debt PenaltyOnConvertibleDebt		usd
CY2023Q1	qpag	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm	P8Y9M
CY2023Q1	qpag	Intrinsic Value Outstanding Options IntrinsicValueOutstandingOptions	0	usd
CY2022Q1	qpag	Intrinsic Value Outstanding Options IntrinsicValueOutstandingOptions	0	usd
CY2023Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	94464	usd
CY2022Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	94466	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	496241594	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	496241594	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	79508625	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	79508625	shares
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Innovative Payment Solutions, Inc.
CY2022Q4	us-gaap	Federal Home Loan Bank Advances Current FederalHomeLoanBankAdvancesCurrent		usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest		usd
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2022Q1	us-gaap	Gross Profit GrossProfit		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	376901679	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	376901679	shares
CY2023Q1	qpag	Penalty On Convertible Debt PenaltyOnConvertibleDebt		usd
CY2022Q1	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders		usd
CY2023Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2023Q1	qpag	Derivative Financial Liability Arising From Convertible Note DerivativeFinancialLiabilityArisingFromConvertibleNote		usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001591913

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
qpag-20230331_cal.xml	Edgar Link	unprocessable
0001213900-23-039367-index-headers.html	Edgar Link	pending
0001213900-23-039367-index.html	Edgar Link	pending
0001213900-23-039367.txt	Edgar Link	pending
0001213900-23-039367-xbrl.zip	Edgar Link	pending
f10q0323ex10-1_innovativepay.htm	Edgar Link	pending
f10q0323ex31-1_innovativepay.htm	Edgar Link	pending
f10q0323ex31-2_innovativepay.htm	Edgar Link	pending
f10q0323ex32-1_innovativepay.htm	Edgar Link	pending
f10q0323ex32-2_innovativepay.htm	Edgar Link	pending
f10q0323_innovativepay.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qpag-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
qpag-20230331_def.xml	Edgar Link	unprocessable
qpag-20230331_lab.xml	Edgar Link	unprocessable
qpag-20230331_pre.xml	Edgar Link	unprocessable
f10q0323_innovativepay_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IPSI
Innovative Payment Solutions, Inc. Stock $ipsi

2023 Q2 Form 10-Q Financial Statement

#000121390023039367 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IPSI Innovative Payment Solutions, Inc. Stock $ipsi

2023 Q2 Form 10-Q Financial Statement

#000121390023039367 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IPSI
Innovative Payment Solutions, Inc. Stock $ipsi